Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 31
Posts 5,125
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
U.S. Stocks Rally; Dow Up Triple-digits
The U.S. stock market surged in morning trade, sending the S&P 500 and Dow Jones Industrial Average into record territory, after a surprise fresh stimulus from the Bank of Japan.
Top Equities Stories Of The Day
Sony Posts Hefty Loss
U.S. Stocks, Bonds Dip on Fed Outlook
Starbucks Sales Growth Disappoints; Delivery Is Coming -- 3rdUpdate
Omega Healthcare to Buy Aviv REIT
Twitter Demotes Product Chief Daniel Graf
InTrade Founders Launch New Forum for Political Predictions
Jefferies Expected to Book up to $15 Million Loss on Toms Shoes Debt, Sources Say -- Update
Biotech Bull Intact But Showing Signs of Age -- Barron's
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 183399 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist